



### LaRDR Sites and Principal Investigators

*(Italics = ethics/ governance approval pending)*

Alfred Hospital: Susan Morgan  
Auckland City Hospital (NZ): Leanne Berkahn  
Austin Health: Eliza Hawkes  
Ballarat Hospital: Geoffrey Chong  
Barwon Health: Sumita Ratnasingam  
Box Hill Hospital: Denise Lee  
Cabrin Health: Melita Kenealy  
Canberra Hospital: Dipti Talaulikar  
Christchurch Hospital (NZ): Emma-Jane McDonald  
Coffs Harbour Health Campus: Kyle Crassini  
Concord Hospital: Judith Trotman  
Epworth Hospital: Miles Prince  
Fiona Stanley Hospital: Allison Barraclough  
Flinders Medical Centre: Kate Manos  
Gold Coast University Hospital: Tara Cochrane  
Gosford Hospital: Tasman Armytage  
Liverpool Hospital: Nicolas Viala  
Monash Health: Stephen Opat  
Northern Health: Teresa Leung  
Peter MacCallum Cancer Centre: Michael Dickinson  
Port Macquarie Base Hospital: Jock Simpson  
Prince of Wales Hospital: Annmarie Bosco  
Princess Alexandra Hospital: Colm Keane  
Rockingham General Hospital: Hun Chuah  
Royal Adelaide Hospital: Pratyush Giri  
Royal Darwin Hospital: Emma Palfreyman  
Royal Hobart Hospital: Anna Johnston  
Royal North Shore Hospital: Luke Coyle  
Royal Perth Hospital: John Balendra  
Sir Charles Gairdner Hospital: Chan Cheah  
St Vincent's Hospital, Melbourne: Matthew Ku  
St Vincent's Hospital, Sydney: Nada Hamad  
Sunshine Coast University Hospital: Manjunath Narayana  
Toowoomba Hospital: Howard Mutsand  
Townsville Hospital: Joel Wright  
Western Health: Duncan Carradice

### LaRDR Steering Committee

Stephen Opat (chair): Monash Health  
Mary Ann Anderson: Peter MacCallum Cancer Centre  
Leanne Berkahn: Auckland Hospital, NZ  
Chan Cheah: Sir Charles Gairdner Hospital  
Michael Dickinson: Peter MacCallum Cancer Centre  
Maher Gandhi: Princess Alexandra Hospital  
Pratyush Giri: Royal Adelaide Hospital  
Eliza Hawkes: Austin Health  
Anna Johnston: Royal Hobart Hospital  
Colm Keane: Princess Alexandra Hospital  
Zoe McQuilten: Monash University  
Stephen Mulligan: Royal North Shore Hospital  
Dipti Talaulikar: Canberra Hospital  
Judith Trotman: Concord Hospital  
Jenne Williams: Consumer representative  
Erica Wood: Monash University

### Working Groups

#### Chronic Lymphocytic Leukaemia

Stephen Mulligan (chair): Royal North Shore Hospital  
Xavier Badoux: St George Hospital  
Gavin Cull: Sir Charles Gairdner Hospital  
Bryone Kuss: Flinders Medical Centre  
Paula Mariton: Princess Alexandra Hospital  
Manjunath Narayana: Sunshine Coast University Hospital  
Stephen Opat: Monash Health  
Sumita Ratnasingam: Geelong Hospital  
Dipti Talaulikar: Canberra Hospital  
Constantine Tam: Peter MacCallum Cancer Centre  
Erica Wood: Monash University

#### Pathology Review

Dipti Talaulikar (chair): Canberra Hospital  
Simone Birch: Princess Alexandra Hospital  
Christina Brown: Royal Prince Alfred Hospital  
David Ellis: Clinpath Pathology  
Yasmin Harvey: Sullivan Nicolaides Pathology  
Sam Hitchins: University of Tasmania  
Sanjiv Jain: Canberra Hospital  
Peter Jessup: Royal Hobart Hospital  
Sunder Juneja: Peter MacCallum Cancer Centre  
Daniel Kearney: Royal Adelaide Hospital  
Beena Kumar: Monash Health  
Stephen Lade: Peter MacCallum Cancer Centre  
Kenneth Lee: University of Sydney  
Connall Leslie: PathWest Laboratory Medicine  
Eileen Long: Hobart Pathology  
Adrienne Morey: Canberra Hospital  
Lakshmi Nath: Clinpath Pathology  
Debbie Norris: QML Pathology  
Andrew Parker: St Vincent's Hospital, Sydney  
Jeremy Parry: Fiona Stanley Hospital

#### Data Validation

Allison Barraclough: Fiona Stanley Hospital  
Joshua Casan: Monash Health  
Tania Cushion: Austin Health  
Aditya Tedjaseputra: Peter MacCallum Cancer Centre

#### LaRDR Administration

Administration: School of Public Health and Preventive Medicine, Monash University  
Coordinating Principal Investigator: Stephen Opat  
Investigators: Erica Wood, Zoe McQuilten, Eliza Hawkes  
Senior Research Officer: Eliza Chung  
Data Manager: Cameron Wellard  
Data Officer: Fiona Chen  
Deputy Director (Operations): Neil Waters  
Registries Project Manager: Naomi Aoki

Welcome to the LaRDR report for 2022! It has been 6 years since we were established. This year was full of growth in recruitment, research output and collaborations. We are excited to share this success with you as contributors and great supporters of the registry.

### MESSAGE FROM THE CHAIR – PROF STEPHEN OPAT

I am pleased to share with you LaRDR's progress in 2022. The registry had 35 participating sites and 5848 registered patients by the end of 2022. We welcomed two New Zealand sites to the registry and they have commenced patient recruitment. We look forward to working with them in 2023.

The first publication from the LaRDR Investigators – [Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry](#) was published in the BMC Medical Research Methodology in October 2022. It was a remarkable milestone for the registry as we documented the success and challenges in establishing a research community for benchmarking clinical practices.


The 2022 BLOOD Conference held in Sydney was an opportunity to showcase the registry. Our investigators presented five abstracts with posters and presentations. We met and greeted many clinicians, researchers, conference attendees, and exhibitors at the exhibition hall. The hybrid Lymphoma Investigator Meeting was highly regarded, especially the panel discussion between lymphoma clinician-researchers, consumer representatives, and advocates. The meeting will encourage long-lasting collaboration and the use of LaRDR data.

I thank the [LaRDR team at Monash University](#), all the site [Principal Investigators and staff](#), [industry and community partners](#), and of course, [our participants](#) for your ongoing support!

### LaRDR ACTIVITIES AND PROGRESS

**Governance and management:** The registry is overseen by a multidisciplinary [Steering Committee](#) and managed by Ms Eliza Chung and the LaRDR team at Monash University's School of Public Health and Preventive Medicine. LaRDR uses an "opt-off" consent model to enable maximum participation. Participants are provided with an information brochure during clinical visits and invited to discuss their potential participation.

**Participation:** 31 sites have contributed data to LaRDR so far. The median age at diagnosis is 64.9 years (IQR 52.9-73.8), and 59.2% are male. The median follow-up is 26.7 months.



The [LaRDR Pathology Review Committee](#) planned for meaningful contributions to the registry. Dr Allison Barraclough and Ms Tania Cushion from the [Data Validation Working Group](#) joined the LaRDR team in the Data Managers meeting. They shared valuable experiences in ascertaining quality in data collection. LaRDR provides [annual benchmarking data reports](#) for participating sites to support practice improvement. Dr Arina Martynchyk and Dr Mary Ann Anderson from the [CLL Subcommittee](#) conducted a data audit. In addition, they improved the design of the collection form based on their expertise in CLL genetics.

Ms Janne Williams, [Consumer Representative](#), facilitated the launch of the [Consumer Reference Group](#), which included patient advocates and peak bodies. The group works with the registry to establish ways to feedback and inform patients about research results.

### REGISTRY PROJECTS

LaRDR provides a platform for registry-based studies, investigator-initiated studies, and international partnerships.

### International Partnerships

A/Prof Eliza Hawkes and Prof Stephen Opat led the LaRDR contribution to the *Hodgkin Lymphoma International Study for*



*Individual Care (HoLISTIC) Consortium*. This collaboration based in the United States published a [manuscript](#) on developing the International Prognostication Index and validated the model using registry data.

A/Prof Eliza Hawkes and Prof H. Miles Prince (Epworth/Peter MacCallum Cancer Centre) continued to lead LaRDR's contribution to the *T-cell Project 2.0*. The collaboration is ongoing, as well as our participation in the *Global NPLHL One Working Group (GLOW) initiative*, which is overseen by Dr Nicole Wong Doo (Concord Hospital).



Prof Chan Cheah and Dr Elizabeth Smyth (Sir Charles Gairdner Hospital) are co-leading a multicentre study on the *Influence of Anti-Retroviral Prophylaxis on Outcomes after R-CHOP Chemotherapy in DLBCL* with National University Health System in Singapore. The study has completed data collection and will commence evaluating the effects of RT-inhibitor prophylaxis on patient outcomes. Prof Chan Cheah is leading LaRDR's participation in a multicentre study on *Long-term outcomes in patients with splenic marginal zone lymphoma treated in the rituximab era* based in Denmark. This study aims to report the treatment outcomes and construct risk prediction scores for clinical outcomes. Data collection is in progress until mid-2023.

### Investigator-Initiated Studies

*ICAN: Immunoglobulin use and outcomes in Chronic lymphocytic leukaemia And Non-Hodgkin lymphoma*



is a registry-based study funded by the National Blood Authority and led by A/Prof Zoe McQuilten from Monash University. ICAN has completed 2-year of data collection on patients with CLL and NHL. The results were analysed and presented at the BLOOD conference to inform infection and treatment patterns by Dr Khaili Chai (PhD Scholar, Monash University).

A/Prof Eliza Hawkes is leading a study of *polatuzumab use in DLBCL patients*. Ms Eliza Chung (registry manager), supervised by Dr Cameron Wellard, has commenced data analysis, and Dr Briony Shaw (PhD Scholar, Monash University) will summarise the results. Dr Diva Baggio (Austin Health), supervised by Prof Stephen Opat (Monash Health) and A/Prof Eliza Hawkes, is summarising the analysis of *ibrutinib use in CLL patients*. A similar *ibrutinib study in MCL patients* was published. We thank LaRDR participating sites for their contributions to these analyses and patients enrolled in the Named Patient Programs.

Dr James Nguyen (Eastern Health), supervised by A/Prof Eliza Hawkes, analysed LaRDR data and published a manuscript on the *characteristics of Hodgkin lymphoma in Australia*. The study identified the clinical, demographic and treatment patterns of Hodgkin lymphoma patients and allowed comparison with other populations. A/Prof Tara Cochrane and Dr ZhongZhen Goh (Gold Coast University Hospital) used the data from the registry and the Australasian Lymphoma Alliance (ALA) to analyse the *Front-line Treatment of Elderly Patients with Classical Hodgkin Lymphoma* and presented at the BLOOD conference. It evaluated the treatment for elderly patients and assessed the outcomes. Data analyses were conducted using SafeHaven, a secure platform for sensitive data sharing supported by the Monash secure e-research platform.

Dr Evangeline Wong (Canberra Hospital), supervised by A/Prof Dipti Talaulikar and Dr Cameron Wellard (LaRDR data manager), presented the Adolescent and Young Adult study results using registry data in BLOOD. Mr Lachlan Coman (Cabrini Health), supervised by A/Prof Melita Keane, presented the results of [an audit on Cabrini LaRDR data](#) in the Cabrini research week.

### REGISTRY MEETINGS and PRESENTATIONS

The registry provides quality data for analyses to add value to existing evidence in improving lymphoma treatments and outcomes. LaRDR has generated 29 conference presentations and 8 peer-reviewed publications so far, with 24 reports and analyses generated in 2022. Dr Khaili Chai, Dr Evangeline Wong, and Dr Zhong Goh had their abstract presented at *BLOOD 2022*. Dr Sumita Ratnasingam and Dr Howard Mustsando also analysed the patient characteristics in metropolitan and non-metropolitan hospitals, while Dr Simran Bhopal analysed that in CLL patients in a BLOOD abstract.



The *2022 ALA/LaRDR/LA Annual Investigator Meeting* chaired by Dr Nicole Wong Doo was held alongside BLOOD 2022 in Sydney, Australia. The *ALA* aims to increase national collaborative lymphoma clinical research output and facilitate international partnerships and industry engagement. *Lymphoma Australia* is a patient advocacy and education organisation with specialist nurses delivering essential services for patients and carers. The meeting included presentations from Prof Chan Cheah (ALA), A/Prof Zoe McQuilten (LaRDR), and Ms Erica Smeaton (LA), and was followed by a panel discussion with consumers. ALA, LaRDR and LA continue encouraging collaboration in lymphoma research across Australia and New Zealand.

### To contact LaRDR

Website: [www.lardr.org](http://www.lardr.org)

Email: [sphpm-lymphoma@monash.edu](mailto:sphpm-lymphoma@monash.edu)

Phone: 1800 811 326

### LaRDR appreciates the support from these organisations:

